干燥综合征相关终点复合指标(CRESS):新型疗效评估指标的开发与验证
本研究开发了用于原发性干燥综合征(pSS)临床试验的复合终点CRESS,包含5个互补项目,总响应定义为5项中至少3项达标。
要点
- CRESS包含5项:临床ESSDAI、患者报告症状、泪腺、唾液腺和血清学指标。
- 总CRESS响应定义为5项中至少3项达到响应标准。
核心结论
- CRESS是用于原发性干燥综合征临床试验的可行、均衡的复合终点,需在前瞻性RCT中进一步验证。
研究设计与样本
- 多学科专家团队选择临床相关项目和候选测量指标,基于专家意见、已发表的最小临床重要改善数据和试验数据(主要为ASAP-III第24周数据)确定各指标响应切点。
- 使用三项独立RCT数据验证CRESS:利妥昔单抗试验(TRACTISS)、阿巴西普跨国试验和托珠单抗试验(ETAP)。
- 计算各CRESS项目响应患者数和百分比,以及主要终点访视时基于总CRESS的响应者百分比(TRACTISS为第48周,其他两项为第24周)。
- 少于三个项目可评估CRESS响应的患者被归为无响应者。
关键数值与推荐
- 全身疾病活动度:临床ESSDAI低于5分。
- 患者报告症状:EULAR干燥综合征患者报告指数(ESSPRI)较基线下降至少1分或至少15%。
- 泪腺项目:基线Schirmer试验或眼染色评分异常者,Schirmer试验增加至少5 mm或眼染色评分降低至少2分;基线正常者,两者均无异常变化。
- 唾液腺项目:非刺激全唾液流率增加至少25%和唾液腺超声检查降低至少25%。
- 血清学:类风湿因子降低至少25%和IgG降低至少10%;总CRESS响应为5项中至少3项响应。
临床怎么用
- CRESS可作为原发性干燥综合征临床试验的复合终点,综合评估全身活动度、患者报告症状、腺体功能和血清学指标。
- 临床使用时需按照定义的切点评估各项响应,总响应需至少3项达标,少于3项可评估者归为无响应。
局限性
- CRESS需在前瞻性随机对照试验中进一步验证。
- 本研究为基于已有试验数据的post-hoc分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent randomised controlled trials (RCTs) in primary Sjögren's syndrome used the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) as their primary endpoint. Given the heterogeneous and complex nature of primary Sjögren's syndrome, it might be more appropriate to also assess other clinically relevant disease features. We aimed to develop a novel composite endpoint for assessing treatment efficacy in patients with primary Sjögren's syndrome: the Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS). METHODS: A multidisciplinary expert team selected clinically relevant items and candidate measurements for inclusion in the composite score. For each measurement, cutoff points for response to treatment were chosen based on expert opinion, previously published data on minimal clinically important improvements, and trial data, primarily the week-24 data of the single-centre ASAP-III trial of abatacept versus placebo. CRESS was validated using data from three independent RCTs: one trial of rituximab (TRACTISS), one of abatacept (multinational trial), and one of tocilizumab (ETAP). We calculated the number and percentage of patients who were responders in the separate CRESS items, and the percentage of responders based on the total CRESS at the primary endpoint visits (week 48 for TRACTISS, week 24 for the other two trials). Patients with fewer than three items available for evaluating CRESS response were imputed as non-responders. FINDINGS: Based on expert opinion, five complementary items were selected to assess response: (1) systemic disease activity by Clinical ESSDAI (less than 5 points); (2) patient-reported symptoms by EULAR Sjögren's Syndrome Patient Reported Index, assessed by a decrease of at least 1 point or at least 15% from baseline; (3) tear gland item by Schirmer's test and ocular staining score, assessed by an increase of at least 5 mm or decrease of at least 2 points, respectively, in patients with abnormal Schirmer's test or ocular staining score findings at baseline, or, in patients with normal baseline values, assessed by no change to abnormal for both; (4) salivary gland item, assessed by unstimulated whole saliva secretion (increase of at least 25%) and salivary gland ultrasonography (decrease of at least 25%); and (5) serology, assessed by rheumatoid factor (decrease of at least 25%) and IgG (decrease of at least 10%). Total CRESS response is defined as response on at least three of five items. Post-hoc assessment of phase 3 trial data showed that CRESS response rates at the primary endpoint visits were 60% (24 of 40) for abatacept versus 18% (seven of 39) for placebo (p<0·0001) in ASAP-III, 49% (33 of 67) for rituximab versus 30% (20 of 66) for placebo (p=0·026) in the TRACTISS trial, 45% (41 of 92) for abatacept versus 32% (30 of 95) for placebo (p=0·067) in the multinational abatacept trial, and 18% (10 of 55) for tocilizumab versus 24% (13 of 55) for placebo (p=0·48) in the ETAP trial. INTERPRETATION: The CRESS is a feasible, well-balanced, composite endpoint for use in trials of primary Sjögren's syndrome. As a next step, the CRESS will require validation in a prospective RCT. FUNDING: None. TRANSLATION: For the Dutch translation of the abstract see Supplementary Materials section.
引用
- Arends S, de Wolff L, van Nimwegen JF, et al. Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. 2021. PMID: 38287621. doi:10.1016/S2665-9913(21)00122-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。